Research study Program year 2023 Source: CMS Open Payments

Ux053-Cl101

Research payments

$319,689

51 payments

Through program year 2023, $319,689 in research payments was reported against Ux053-Cl101, across 51 payments, paid by Ultragenyx Pharmaceutical Inc..

Paid by: Ultragenyx Pharmaceutical Inc.
ClinicalTrials.gov: No trial number was reported for this study

By program year

3 rows

Year	Kind	Amount	Payments
2023	Research	$64,353	16
2022	Research	$217,354	34
2021	Research	$37,982	1

Breakdown

Who paid Research payments · program years 2021–2023

Ultragenyx Pharmaceutical Inc. $319,689 51 payments

Who received the money Research payments · program years 2021–2023

Uci Medical Center Teaching hospital · CA $128,660 20 payments
The University Of Texas Health Organisation paid for research $105,813 13 payments
The Childrens Hospital Of Philadelphia Organisation paid for research $53,709 9 payments
Rare Disease Research LLC Organisation paid for research $31,507 9 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

4 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.